Evergreen Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

Evergreen Capital Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-171,338	Closed	-$372K	–	1643
2026 Q1	$372K	Hold	171,338	–	–	0.01%	985
2025 Q4	$308K	Hold	171,338	–	–	0.01%	1017
2025 Q3	$380K	Hold	171,338	–	–	0.01%	808
2025 Q2	$254K	Buy	+171,338	New	+$351K	0.01%	881

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Evergreen Capital Management's PLX Position: Q2 2026 in Review

Evergreen Capital Management sold out of Protalix BioTherapeutics (PLX) in Q2 2026, closing a stake of 171,338 shares — an estimated $372K sold.

Evergreen Capital Management first reported a position in PLX in Q2 2025 and held it in 4 quarters. The position peaked at $380K in Q3 2025. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Evergreen Capital Management reported no remaining Protalix BioTherapeutics position as of Q2 2026 after selling out during the quarter.
Evergreen Capital Management sold 171,338 Protalix BioTherapeutics shares in Q2 2026, an estimated $372K.
Evergreen Capital Management first reported a position in Protalix BioTherapeutics in Q2 2025 and held it in 4 quarters.
Evergreen Capital Management's Protalix BioTherapeutics position peaked at $380K in Q3 2025.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Evergreen Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.